Peter W Hunt Selected Research

Art Therapy

1/2022	Plasma CD16+ Extracellular Vesicles Associate with Carotid Artery Intima-Media Thickness in HIV+ Adults on Combination Antiretroviral Therapy.
1/2022	IFN-α blockade during ART-treated SIV infection lowers tissue vDNA, rescues immune function, and improves overall health.
12/2021	Internalized stigma, depressive symptoms, and the modifying role of antiretroviral therapy: A cohort study in rural Uganda.
6/2021	Changes in Immune Activation During Pregnancy and the Postpartum Period in Treated HIV Infection.
1/2021	Abnormal Levels of Some Biomarkers of Immune Activation Despite Very Early Treatment of Human Immunodeficiency Virus.
12/2019	Antiretroviral Therapy Adherence Interruptions Are Associated With Systemic Inflammation Among Ugandans Who Achieved Viral Suppression.
1/2019	Lower Pretreatment Gut Integrity Is Independently Associated With Fat Gain on Antiretroviral Therapy.
1/2018	Increasing Prevalence of HIV Pretreatment Drug Resistance in Women But Not Men in Rural Uganda During 2005-2013.
1/2018	Changes in Inflammation but Not in T-Cell Activation Precede Non-AIDS-Defining Events in a Case-Control Study of Patients on Long-term Antiretroviral Therapy.
1/2018	Brief Report: Higher ART Adherence Is Associated With Lower Systemic Inflammation in Treatment-Naive Ugandans Who Achieve Virologic Suppression.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter W Hunt Research Topics

Disease

36	HIV Infections (HIV Infection) 03/2022 - 12/2006
35	Inflammation (Inflammations) 01/2022 - 04/2010
31	Acquired Immunodeficiency Syndrome (AIDS) 01/2022 - 03/2010
26	Infections 04/2022 - 01/2012
18	Viremia 01/2019 - 09/2003
10	Disease Progression 01/2017 - 03/2006
9	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 03/2010
4	Neoplasms (Cancer) 01/2021 - 03/2010
4	Fibrosis (Cirrhosis) 01/2018 - 04/2015
4	Atherosclerosis 06/2012 - 06/2009
3	Macular Degeneration (Age-Related Maculopathy) 01/2022 - 01/2018
3	Tuberculosis (Tuberculoses) 06/2021 - 09/2011
3	Myocardial Infarction 10/2020 - 09/2009
3	Sepsis (Septicemia) 01/2019 - 01/2017
3	Hepatitis C 01/2019 - 11/2013
2	Alcoholism (Alcohol Abuse) 03/2022 - 12/2015
2	Virus Diseases (Viral Diseases) 01/2022 - 01/2019
2	Kaposi Sarcoma (Kaposi's Sarcoma) 01/2021 - 11/2015
2	Atherosclerotic Plaque (Atheroma) 01/2019 - 01/2017
2	Persistent Infection 01/2019 - 01/2017
2	Insulin Resistance 01/2019 - 01/2019
2	Necrosis 01/2018 - 01/2012
2	Hypertension (High Blood Pressure) 12/2016 - 10/2015
2	Carotid Artery Diseases 02/2016 - 06/2012
1	Nematode Infections 04/2022
1	Zika Virus Infection 01/2022
1	Cataract (Cataracts) 01/2022
1	COVID-19 01/2022
1	Type 2 Diabetes Mellitus (MODY) 10/2020
1	Genetic Risk Score 10/2020
1	Tics (Tic) 01/2020
1	Hyperlipidemias (Hyperlipidemia) 01/2019
1	Pneumonia (Pneumonitis) 01/2019
1	Ischemic Stroke 01/2019
1	Body Weight (Weight, Body) 01/2019
1	Obstructive Lung Diseases (Obstructive Lung Disease) 01/2019
1	Lung Injury 01/2019
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2019
1	Digestive System Diseases 01/2019
1	Eye Diseases (Eye Disease) 01/2018
1	Liver Neoplasms (Liver Cancer) 01/2018
1	Thrombophilia 01/2018
1	Osteoporosis 01/2018

Drug/Important Bio-Agent (IBA)

21	Biomarkers (Surrogate Marker)IBA 01/2022 - 04/2010
14	RNA (Ribonucleic Acid)IBA 01/2020 - 04/2004
10	KynurenineIBA 03/2022 - 07/2013
9	Tryptophan (L-Tryptophan)FDA Link 03/2022 - 07/2013
8	Interleukin-6 (Interleukin 6)IBA 01/2019 - 07/2013
7	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 03/2011
6	Lipopolysaccharide ReceptorsIBA 01/2022 - 10/2014
5	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2016
5	C-Reactive ProteinIBA 01/2022 - 04/2012
5	CytokinesIBA 01/2020 - 07/2013
4	Pharmaceutical PreparationsIBA 01/2020 - 03/2006
4	fibrin fragment D (D-dimer)IBA 01/2019 - 10/2014
4	VaccinesIBA 12/2014 - 05/2008
4	HLA-DR Antigens (HLA-DR)IBA 04/2011 - 03/2006
3	Biological ProductsIBA 01/2022 - 08/2011
3	Fatty Acid-Binding ProteinsIBA 01/2022 - 01/2019
3	Peptide Hydrolases (Proteases)FDA Link 11/2021 - 03/2006
3	Retinaldehyde (Retinal)IBA 01/2019 - 07/2017
3	Oxygen (Dioxygen)IBA 01/2019 - 01/2017
2	phosphatidylethanolIBA 03/2022 - 12/2015
2	InterleukinsIBA 01/2022 - 01/2019
2	Neutralizing AntibodiesIBA 01/2022 - 12/2016
2	InterferonsIBA 01/2022 - 01/2019
2	Immunoglobulin G (IgG)IBA 01/2021 - 06/2012
2	Antiviral Agents (Antivirals)IBA 01/2021 - 04/2010
2	AntibodiesIBA 12/2019 - 05/2019
2	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2019 - 10/2014
2	Atazanavir Sulfate (Reyataz)FDA Link 01/2019 - 01/2018
2	BilirubinIBA 01/2019 - 01/2018
2	abacavir (Ziagen)FDA Link 10/2017 - 09/2009
2	Interleukin-17 (Interleukin 17)IBA 08/2014 - 05/2010
1	4-toluenesulfonyl fluoride (TSF)IBA 04/2022
1	Glial Fibrillary Acidic ProteinIBA 01/2022
1	Janus Kinase InhibitorsIBA 01/2022
1	ruxolitinibIBA 01/2022
1	T Cell Transcription Factor 1IBA 01/2021
1	Immunoglobulin E (IgE)IBA 01/2021
1	Carbon MonoxideIBA 01/2021
1	Integrase InhibitorsIBA 01/2021
1	LipidsIBA 10/2020
1	Indicators and Reagents (Reagents)IBA 12/2019
1	Matrix Metalloproteinases (MMPs)IBA 10/2019
1	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2019
1	CHDI-340246IBA 01/2019
1	Pulmonary Surfactant-Associated Protein D (Surfactant Protein D)IBA 01/2019
1	Fibrinogen (Factor I)FDA Link 01/2019
1	Kynurenine 3-Monooxygenase (Kynurenine 3 Monooxygenase)IBA 01/2019
1	Hyaluronic Acid (Hyaluronan)IBA 01/2019
1	Interferon-gamma (Interferon, gamma)IBA 01/2019
1	CholesterolIBA 11/2018
1	Nevirapine (Viramune)FDA Link 01/2018
1	Serum AlbuminIBA 01/2018
1	PerforinIBA 01/2018
1	ThymidineIBA 01/2018

Therapy/Procedure

45	Therapeutics 01/2021 - 09/2003
34	Art Therapy 01/2022 - 03/2010
6	Highly Active Antiretroviral Therapy (HAART) 01/2019 - 10/2010